TABLE 3.
Numbers and percentages of subjects showing SBA titers of ≥4 at baseline and after each dose of MenBvac
| Target strain | No. of subjects with SBA titers of ≥4/total no. of subjects tested (%)
|
||||
|---|---|---|---|---|---|
| Baseline | 6 wk after dose 1 | 6 wk after dose 2 | 6 wk after dose 3 | 1 yr after dose 3 | |
| 44/76-SL | 9/30 (30) | 23/31 (74.2) | 24/28 (85.7) | 22/25 (88) | 13/23 (56.5) |
| NZ 98/254 | 10/28 (35.7) | 20/31 (64.5) | 16/25 (64) | 17/25 (68) | 12/24 (50) |
| M01 240013 | 20/28 (71.4) | 23/31 (74.2) | 21/25 (84) | 21/25 (84) | 18/24 (75) |
| M01 240101 | 21/28 (75) | 26/31 (83.9) | 17/24 (70.8) | 23/25 (92) | 17/24 (70.8) |
| M01 240149 | 13/28 (46.4) | 17/31 (54.8) | 14/25 (56) | 14/25 (56) | 13/24 (54.2) |
| M01 240185 | 11/28 (39.3) | 15/31 (48.4) | 11/25 (44) | 13/25 (52) | 8/24 (33.3) |
| M01 240355 | 17/28 (60.7) | 25/31 (80.7) | 20/25 (80) | 22/25 (88) | 18/24 (75) |